Published in J Geriatr Psychiatry Neurol on October 11, 2010
Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol (2012) 2.20
α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease. Pharmacol Rev (2011) 1.29
Is pesticide use related to Parkinson disease? Some clues to heterogeneity in study results. Environ Health Perspect (2012) 1.22
The MAPT H1 haplotype is associated with tangle-predominant dementia. Acta Neuropathol (2012) 1.05
Knowledge of and interest in genetic results among Parkinson disease patients and caregivers. J Genet Couns (2013) 1.01
Polyphenols: multipotent therapeutic agents in neurodegenerative diseases. Oxid Med Cell Longev (2013) 0.98
Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models. Neurobiol Dis (2012) 0.94
Substitution p.A350V in Na⁺/Mg²⁺ exchanger SLC41A1, potentially associated with Parkinson's disease, is a gain-of-function mutation. PLoS One (2013) 0.91
Move for change part I: a European survey evaluating the impact of the EPDA Charter for People with Parkinson's disease. Eur J Neurol (2011) 0.91
The bad, the good, and the ugly about oxidative stress. Oxid Med Cell Longev (2012) 0.91
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice. Brain (2012) 0.91
SNCA and MAPT genes: Independent and joint effects in Parkinson disease in the Italian population. Parkinsonism Relat Disord (2011) 0.90
Regulation of parkin and PINK1 by neddylation. Hum Mol Genet (2012) 0.90
Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation. Front Mol Neurosci (2014) 0.89
Functional paraoxonase 1 variants modify the risk of Parkinson's disease due to organophosphate exposure. Environ Int (2013) 0.88
Glucocerebrosidase L444P mutation confers genetic risk for Parkinson's disease in central China. Behav Brain Funct (2012) 0.87
Amyloid oligomer neurotoxicity, calcium dysregulation, and lipid rafts. Int J Alzheimers Dis (2011) 0.87
The effects of morphine on Parkinson's-related genes PINK1 and PARK2. Med Sci Monit Basic Res (2014) 0.86
Genetic variability in SNCA and Parkinson's disease. Neurogenetics (2011) 0.85
Tom70 is essential for PINK1 import into mitochondria. PLoS One (2013) 0.84
The Diagnostic and Differential Diagnosis Utility of Cerebrospinal Fluid α -Synuclein Levels in Parkinson's Disease: A Meta-Analysis. Parkinsons Dis (2015) 0.83
Ceftriaxone ameliorates motor deficits and protects dopaminergic neurons in 6-hydroxydopamine-lesioned rats. ACS Chem Neurosci (2011) 0.83
Exposure to glyphosate- and/or Mn/Zn-ethylene-bis-dithiocarbamate-containing pesticides leads to degeneration of γ-aminobutyric acid and dopamine neurons in Caenorhabditis elegans. Neurotox Res (2011) 0.83
Cognitive Status Correlates with CXCL10/IP-10 Levels in Parkinson's Disease. Parkinsons Dis (2014) 0.82
Expression of human E46K-mutated α-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment. Exp Neurol (2012) 0.82
Identification of an artificial peptide motif that binds and stabilizes reduced human DJ-1. J Struct Biol (2011) 0.82
A powerful yeast model to investigate the synergistic interaction of α-synuclein and tau in neurodegeneration. PLoS One (2013) 0.81
The neuropathology of traumatic brain injury. Handb Clin Neurol (2015) 0.81
Considerations on the role of environmental toxins in idiopathic Parkinson's disease pathophysiology. Transl Neurodegener (2014) 0.80
Accurate prediction of a minimal region around a genetic association signal that contains the causal variant. Eur J Hum Genet (2013) 0.80
The benefits of humanized yeast models to study Parkinson's disease. Oxid Med Cell Longev (2013) 0.80
Kynurenines in Parkinson's disease: therapeutic perspectives. J Neural Transm (Vienna) (2011) 0.80
No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts. PLoS One (2015) 0.79
Risk prediction for complex diseases: application to Parkinson disease. Genet Med (2012) 0.79
Association mapping of the PARK10 region for Parkinson's disease susceptibility genes. Parkinsonism Relat Disord (2013) 0.79
Gaucher disease and the synucleinopathies: refining the relationship. Orphanet J Rare Dis (2012) 0.79
Integrative analysis of common neurodegenerative diseases using gene association, interaction networks and mRNA expression data. AMIA Jt Summits Transl Sci Proc (2012) 0.79
Macroautophagy and the proteasome are differently involved in the degradation of alpha-synuclein wild type and mutated A30P in an in vitro inducible model (PC12/TetOn). Neuroscience (2011) 0.78
Polymorphisms of DRD2 and DRD3 genes and Parkinson's disease: A meta-analysis. Biomed Rep (2014) 0.77
Lipopolyplex for Therapeutic Gene Delivery and Its Application for the Treatment of Parkinson's Disease. Front Aging Neurosci (2016) 0.77
Deficiency of Parkinson's disease-related gene Fbxo7 is associated with impaired mitochondrial metabolism by PARP activation. Cell Death Differ (2016) 0.77
Move for Change Part II: a European survey evaluating the impact of the EPDA Charter for people with Parkinson's disease. Eur J Neurol (2012) 0.77
Rare coding SNP in DZIP1 gene associated with late-onset sporadic Parkinson's disease. Sci Rep (2012) 0.76
LRRK2 G2385R and R1628P mutations are associated with an increased risk of Parkinson's disease in the Malaysian population. Biomed Res Int (2014) 0.76
Genetic association of cyclooxygenase-2 gene polymorphisms with Parkinson's disease susceptibility in Chinese Han population. Int J Clin Exp Pathol (2015) 0.76
Association between ubiquitin carboxy-terminal hydrolase-L1 S18Y variant and risk of Parkinson's disease: the impact of ethnicity and onset age. Neurol Sci (2014) 0.76
ERKed by LRRK2: a cell biological perspective on hereditary and sporadic Parkinson's disease. Biochim Biophys Acta (2013) 0.76
Gaucher-Associated Parkinsonism. Cell Mol Neurobiol (2015) 0.75
The effect of MAPT haplotype on neocortical Lewy body pathology in Parkinson disease. J Neural Transm (Vienna) (2016) 0.75
Genetic association of NOS1 exon18, NOS1 exon29, ABCB1 1236C/T, and ABCB1 3435C/T polymorphisms with the risk of Parkinson's disease: A meta-analysis. Medicine (Baltimore) (2016) 0.75
spargel, the PGC-1α homologue, in models of Parkinson disease in Drosophila melanogaster. BMC Neurosci (2015) 0.75
Analysis of Thr12Met and Ala1144Thr mutations of the ATP13A2 gene in Parkinson's disease patients in Xinjiang Uygur and Han ethnic groups. Med Sci Monit (2014) 0.75
Emerging preclinical pharmacological targets for Parkinson's disease. Oncotarget (2016) 0.75
Association of NQO1 and TNF polymorphisms with Parkinson's disease: A meta-analysis of 15 genetic association studies. Biomed Rep (2014) 0.75
Inhibition by Multifunctional Magnetic Nanoparticles Loaded with Alpha-Synuclein RNAi Plasmid in a Parkinson's Disease Model. Theranostics (2017) 0.75
What can imaging tell us about cognitive impairment and dementia? World J Radiol (2016) 0.75
Relationship between LRRK2 R1628P polymorphism and Parkinson's disease in Asian populations. Oncotarget (2016) 0.75
Induced Pluripotent Stem Cell Modeling of Gaucher's Disease: What Have We Learned? Int J Mol Sci (2017) 0.75
A molecular analysis of the GBA gene in Caucasian South Africans with Parkinson's disease. Mol Genet Genomic Med (2017) 0.75
Cryo-EM analysis of homodimeric full-length LRRK2 and LRRK1 protein complexes. Sci Rep (2017) 0.75
Alzheimer's Disease and Paraoxonase 1 (PON1) Gene Polymorphisms. Open Biochem J (2017) 0.75
Oxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications. Oxid Med Cell Longev (2017) 0.75
Variable frequency of LRRK2 variants in the Latin American research consortium on the genetics of Parkinson's disease (LARGE-PD), a case of ancestry. NPJ Parkinsons Dis (2017) 0.75
Reduced Circulating Levels of miR-433 and miR-133b Are Potential Biomarkers for Parkinson's Disease. Front Cell Neurosci (2017) 0.75
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature (1998) 21.49
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
alpha-Synuclein locus triplication causes Parkinson's disease. Science (2003) 20.20
Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science (2004) 15.91
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron (2004) 13.99
A common inversion under selection in Europeans. Nat Genet (2005) 13.66
Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet (1998) 12.92
Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature (2006) 11.91
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science (2002) 9.90
The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol (2004) 9.62
Neurodegenerative tauopathies. Annu Rev Neurosci (2001) 9.53
Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain (1991) 8.16
Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet (2009) 8.11
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet (2000) 7.83
Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet (2004) 7.69
Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci U S A (2003) 7.57
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med (2009) 7.53
RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. Proc Natl Acad Sci U S A (1999) 7.32
Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res (2004) 7.06
Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A (2005) 6.98
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science (2000) 6.28
Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med (1998) 5.49
Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol (1998) 5.42
Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet (2004) 5.06
Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet (2008) 5.04
Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med (2000) 4.98
Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem (2004) 4.86
The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc Natl Acad Sci U S A (2004) 4.76
Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet (2006) 4.61
The ubiquitin pathway in Parkinson's disease. Nature (1998) 4.48
Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet (2010) 4.47
Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem (2003) 4.36
Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA (2006) 4.26
Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet (2010) 4.26
Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science (2001) 4.18
Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet (1999) 4.17
Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet (2006) 4.01
LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med (2006) 3.90
DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep (2004) 3.84
Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci U S A (2005) 3.83
Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science (1996) 3.79
Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum Mol Genet (2005) 3.76
Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol (2006) 3.72
Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry (2000) 3.62
Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol (2009) 3.62
DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun (1997) 3.61
Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet (2009) 3.56
Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat (2008) 3.53
Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet (2003) 3.51
The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet (2005) 3.49
Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann Neurol (2004) 3.37
Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet (2005) 3.29
Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron (2009) 3.15
Parkinson's disease. Lancet (2004) 3.08
Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development (2004) 3.03
Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A (2005) 3.00
A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol (2002) 3.00
Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res (2002) 2.96
Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann Neurol (2008) 2.95
LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med (2006) 2.93
Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol (2002) 2.92
The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann Neurol (2003) 2.80
Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology (2007) 2.72
Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Hum Mol Genet (2005) 2.72
GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry (2007) 2.71
Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology (2005) 2.69
Lipid rafts mediate the synaptic localization of alpha-synuclein. J Neurosci (2004) 2.65
Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci (2004) 2.64
Glial reactions in Parkinson's disease. Mov Disord (2008) 2.62
alpha-Synuclein membrane interactions and lipid specificity. J Biol Chem (2000) 2.60
Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet (2005) 2.56
Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum Mol Genet (2001) 2.52
ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology (2007) 2.51
Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J Biol Chem (2006) 2.50
Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol (2001) 2.50
PINK1 protein in normal human brain and Parkinson's disease. Brain (2006) 2.49
Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab (2004) 2.46
Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology (2000) 2.45
Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology (1998) 2.37
PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol (2004) 2.30
Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet (2005) 2.28
Parkin-deficient mice are not a robust model of parkinsonism. Proc Natl Acad Sci U S A (2005) 2.27
Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet (2003) 2.26
Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. J Biol Chem (2005) 2.26
Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology (2006) 2.25
DJ-1 up-regulates glutathione synthesis during oxidative stress and inhibits A53T alpha-synuclein toxicity. J Biol Chem (2005) 2.24
Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol (2003) 2.23
Familial Parkinson's disease-associated L166P mutation disrupts DJ-1 protein folding and function. J Biol Chem (2003) 2.21
The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain (2003) 2.17
L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system. J Biol Chem (2003) 2.12
A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics (2006) 2.10
DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin. Free Radic Res (2001) 2.09
Oxidized forms of peroxiredoxins and DJ-1 on two-dimensional gels increased in response to sublethal levels of paraquat. Free Radic Res (2001) 2.08
Association of glucocerebrosidase mutations with dementia with lewy bodies. Arch Neurol (2009) 2.06
Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology (2004) 2.05
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet (2010) 4.47
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet (2012) 4.27
DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain (2010) 3.57
Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet (2005) 3.29
Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann Neurol (2008) 2.95
Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol (2011) 2.84
Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee. PLoS Genet (2011) 2.28
Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol (2012) 2.20
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology (2012) 2.19
Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study. Lancet Neurol (2006) 1.92
Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. Arch Neurol (2008) 1.89
Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patients. Ann Neurol (2007) 1.88
Regulation of drug reward by cAMP response element-binding protein: evidence for two functionally distinct subregions of the ventral tegmental area. J Neurosci (2005) 1.84
CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov Disord (2010) 1.71
Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. Mov Disord (2008) 1.61
SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol (2010) 1.54
Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain (2011) 1.53
Genetic association between alpha-synuclein and idiopathic Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet (2008) 1.50
Lrrk2-associated parkinsonism is a major cause of disease in Northern Spain. Parkinsonism Relat Disord (2007) 1.47
LRRK2: a common pathway for parkinsonism, pathogenesis and prevention? Trends Mol Med (2006) 1.44
Exploring gene-environment interactions in Parkinson's disease. Hum Genet (2008) 1.43
Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett (2010) 1.42
APOE ε4 increases risk for dementia in pure synucleinopathies. JAMA Neurol (2013) 1.41
Phosphorylated α-synuclein in Parkinson's disease. Sci Transl Med (2012) 1.29
Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics. Mov Disord (2006) 1.28
Genotype-controlled analysis of plasma dopamine beta-hydroxylase activity in psychotic unipolar major depression. Biol Psychiatry (2002) 1.23
LRRK2 mutations and risk variants in Japanese patients with Parkinson's disease. Mov Disord (2009) 1.22
LRRK2 mutations in patients with Parkinson's disease from Peru and Uruguay. Parkinsonism Relat Disord (2008) 1.16
Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactive neuronal inclusions. Acta Neuropathol (2006) 1.13
Pacific Northwest Udall Center of excellence clinical consortium: study design and baseline cohort characteristics. J Parkinsons Dis (2013) 1.12
Mutations in the dopamine beta-hydroxylase gene are associated with human norepinephrine deficiency. Am J Med Genet (2002) 1.11
Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation. Mov Disord (2005) 1.10
Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. Arch Neurol (2006) 1.09
Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. Am J Pathol (2011) 1.04
DJ-1 isoforms in whole blood as potential biomarkers of Parkinson disease. Sci Rep (2012) 1.02
Replication of MAPT and SNCA, but not PARK16-18, as susceptibility genes for Parkinson's disease. Mov Disord (2011) 1.01
Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease. Parkinsonism Relat Disord (2010) 0.99
Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: an exploratory analysis. J Neurol Neurosurg Psychiatry (2010) 0.98
A genotype-controlled analysis of plasma dopamine beta-hydroxylase in healthy and alcoholic subjects: evidence for alcohol-related differences in noradrenergic function. Biol Psychiatry (2002) 0.97
Association of Parkinson disease with structural and regulatory variants in the HLA region. Am J Hum Genet (2013) 0.96
Altered splicing of ATP6AP2 causes X-linked parkinsonism with spasticity (XPDS). Hum Mol Genet (2013) 0.95
Chemokines (RANTES and MCP-1) and chemokine-receptors (CCR2 and CCR5) gene polymorphisms in Alzheimer's and Parkinson's disease. Neurosci Lett (2004) 0.95
Clinical and biochemical differences in patients having Parkinson disease with vs without GBA mutations. JAMA Neurol (2013) 0.95
Glycoproteomics in neurodegenerative diseases. Mass Spectrom Rev (2009) 0.94
Identification of a novel Parkinson's disease locus via stratified genome-wide association study. BMC Genomics (2014) 0.93
Evidence for more than one Parkinson's disease-associated variant within the HLA region. PLoS One (2011) 0.92
DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function. Neurobiol Aging (2011) 0.92
A search for SNCA 3' UTR variants identified SNP rs356165 as a determinant of disease risk and onset age in Parkinson's disease. J Mol Neurosci (2011) 0.91
Genotypic and haplotypic associations of the DBH gene with plasma dopamine beta-hydroxylase activity in African Americans. Eur J Hum Genet (2007) 0.91
Digenic parkinsonism: investigation of the synergistic effects of PRKN and LRRK2. Neurosci Lett (2006) 0.91
Association between the TNFalpha-308 A/G polymorphism and the onset-age of Alzheimer disease. Am J Med Genet (2002) 0.89
Genotype-phenotype correlates in Taiwanese patients with early-onset recessive Parkinsonism. Mov Disord (2009) 0.87
Cognitive profile of LRRK2-related Parkinson's disease. Mov Disord (2015) 0.87
Lack of evidence for an association between UCHL1 S18Y and Parkinson's disease. Eur J Neurol (2007) 0.87
C9orf72 hexanucleotide repeat expansion and Guam amyotrophic lateral sclerosis-Parkinsonism-dementia complex. JAMA Neurol (2013) 0.86
Lrrk2 R1441G-related Parkinson's disease: evidence of a common founding event in the seventh century in Northern Spain. Neurogenetics (2009) 0.86
Evaluation of mild cognitive impairment subtypes in Parkinson's disease. Mov Disord (2014) 0.86
Haplotype analysis of Lrrk2 R1441H carriers with parkinsonism. Parkinsonism Relat Disord (2008) 0.86
LRRK2 mutations and Parkinsonism. Lancet (2005) 0.86
People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance. Mov Disord (2014) 0.86
Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity. Acta Neuropathol Commun (2015) 0.84
Haplotype-controlled analysis of the association of a non-synonymous single nucleotide polymorphism at DBH (+ 1603C --> T) with plasma dopamine beta-hydroxylase activity. Am J Med Genet B Neuropsychiatr Genet (2005) 0.84
GCH1 in early-onset Parkinson's disease. Mov Disord (2009) 0.83
DBH -1021C-->T does not modify risk or age at onset in Parkinson's disease. Ann Neurol (2007) 0.83
Ashkenazi Parkinson's disease patients with the LRRK2 G2019S mutation share a common founder dating from the second to fifth centuries. Neurogenetics (2009) 0.83
Cheek cell-derived α-synuclein and DJ-1 do not differentiate Parkinson's disease from control. Neurobiol Aging (2013) 0.83
Analysis of the LRRK2 G2019S mutation in Alzheimer Disease. Arch Neurol (2006) 0.82
A revised allele frequency estimate and haplotype analysis of the DBH deficiency mutation IVS1+2T --> C in African- and European-Americans. Am J Med Genet A (2003) 0.82
Visualizing disease associations: graphic analysis of frequency distributions as a function of age using moving average plots (MAP) with application to Alzheimer's and Parkinson's disease. Genet Epidemiol (2010) 0.82
Validity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson's disease. Genet Test (2006) 0.81
Variations in the dopamine beta-hydroxylase gene are not associated with the autonomic disorders, pure autonomic failure, or multiple system atrophy. Am J Med Genet A (2003) 0.81
Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD. Parkinsonism Relat Disord (2005) 0.80
Risk prediction for complex diseases: application to Parkinson disease. Genet Med (2012) 0.79
Targeted discovery and validation of plasma biomarkers of Parkinson's disease. J Proteome Res (2014) 0.79
A novel X-linked four-repeat tauopathy with Parkinsonism and spasticity. Mov Disord (2010) 0.79
The UCHL1 S18Y polymorphism and Parkinson's disease in a Japanese population. Parkinsonism Relat Disord (2011) 0.78
Pathogenicity of the Lrrk2 R1514Q substitution in Parkinson's disease. Mov Disord (2007) 0.77
Mutational screening of PARKIN identified a 3' UTR variant (rs62637702) associated with Parkinson's disease. J Mol Neurosci (2012) 0.77
Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease. Mov Disord (2011) 0.76
Lrrk2 p.Q1111H substitution and Parkinson's disease in Latin America. Parkinsonism Relat Disord (2011) 0.75
Common variation in the LRRK2 gene is a risk factor for Parkinson's disease. Mov Disord (2012) 0.75
Novel Lrrk2-p.S1761R mutation is not a common cause of Parkinson's disease in Spain. Mov Disord (2013) 0.75
The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson's disease, adds to the complexity of a mutational hotspot. Am J Med Genet B Neuropsychiatr Genet (2016) 0.75
Genetic polymorphism at codon 129 of the prion protein gene is not associated with multiple sclerosis. Arch Neurol (2009) 0.75